These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31557562)

  • 1. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
    Hellyer JA; Gubens MA; Cunanan KM; Padda SK; Burns M; Spittler AJ; Riess JW; San Pedro-Salcedo M; Ramchandran KJ; Neal JW; Wakelee HA; Loehrer PJ
    Lung Cancer; 2019 Nov; 137():71-75. PubMed ID: 31557562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
    Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
    J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
    Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
    J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis.
    Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T
    Jpn J Clin Oncol; 2014 Nov; 44(11):1120-2. PubMed ID: 25240023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
    J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
    Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
    Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
    J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
    Galsky MD; Hahn NM; Wong B; Lee KM; Argiriadi P; Albany C; Gimpel-Tetra K; Lowe N; Shahin M; Patel V; Tsao CK; Oh WK
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1259-65. PubMed ID: 26464352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
    Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
    Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
    Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
    Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.
    Koizumi T; Agatsuma T; Ichiyama T; Yokoyama T; Ushiki A; Komatsu Y; Tanabe T; Kobayashi T; Yoshikawa S; Yasuo M; Yamamoto H; Kubo K; Hachiya T
    Med Oncol; 2010 Jun; 27(2):392-6. PubMed ID: 19415537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
    Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
    Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
    Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
    Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
    Ikeda T; Takemoto S; Senju H; Gyotoku H; Taniguchi H; Shimada M; Dotsu Y; Umeyama Y; Tomono H; Kitazaki T; Fukuda M; Soda H; Yamaguchi H; Fukuda M; Mukae H
    Thorac Cancer; 2020 Jul; 11(7):1972-1978. PubMed ID: 32462731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
    Yoshioka H; Katakami N; Okamoto H; Iwamoto Y; Seto T; Takahashi T; Sunaga N; Kudoh S; Chikamori K; Harada M; Tanaka H; Saito H; Saka H; Takeda K; Nogami N; Masuda N; Harada T; Kitagawa H; Horio H; Yamanaka T; Fukuoka M; Yamamoto N; Nakagawa K
    Ann Oncol; 2017 Feb; 28(2):285-291. PubMed ID: 28426104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.